This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Grace Powers Monaco, JD; M. Gail Gottlieb

JAMA. 1987;258(22):3296-3297.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE FOOD and Drug Administration (FDA) has finalized new rules to facilitate the availability, outside of clinical trials, of promising new therapies being investigated in clinical trials. Effective June 22, 1987, investigational new drugs (INDs) have been available to treat "desperately" ill patients (those patients with serious or immediately life-threatening illnesses) as early in the drug development phase as possible. These new therapeutic options are referred to as "treatment INDs.¹ Patient access to these drugs, usually limited to clinical trials, is conditioned on an absence of comparable or satisfactory therapy and on adequate enrollment in ongoing clinical trials.

The FDA postulates that requiring adequate clinical trial enrollment before access to treatment INDs is permitted will prevent the undermining of the clinical trial process. Only time will tell whether the trial process will be harmed. However, without this provision, not included in the rule as initially proposed, the FDA would have . . . [Full Text PDF of this Article]

Footnotes
Ms Monaco is a partner with White, Fine & Verville, Washington, DC. Ms Gottlieb is a summer law clerk with White, Fine & Verville and is a student at the American University School of Law, Washington, DC.

Reprint requests to White, Fine & Verville, Suite 1100, 1156 15th St NW, Washington, DC 20005 (Ms Monaco).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?